Figures computed from official regulatory filings — .
Analysttarget 12 USD (+2464%)
Ownershipinsiders 60.42% · institutions 11.14% · short 0.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Estrella Immunopharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
4 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Liu Cheng | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Xu Jiandong | Exercise | $81.5K | SEC |
| Xu Jiandong | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Xu Jiandong | Buy | $104 | conv 54First in 12mo | SEC |
| Xu Jiandong | Buy | $1.3K | conv 30 | SEC |
| Xu Jiandong | Buy | $1.2K | conv 42 | SEC |
| Liu Cheng | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Xu Jiandong | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Xu Jiandong | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Liu Cheng | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| ALTMAN JEFFREY Atrack record | Other | $2.8M | SEC |
| Li Jianwei | Buy | $44.7B | conv 40 | SEC |